Sarah Heeson
Roche (United Kingdom)(GB)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies
Most-Cited Works
- → Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer(2015)2,084 cited
- → Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops(2004)539 cited
- → Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study(2020)153 cited
- → An intragenic methylated region in the imprinted Igf2 gene augments transcription(2001)149 cited
- → Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy(2017)121 cited
- → Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial(2022)51 cited
- → Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab(2017)40 cited
- → Final Overall Survival (Os) Analysis from the Cleopatra Study of First-Line (1L) Pertuzumab (Ptz), Trastuzumab (T), and Docetaxel (D) in Patients (Pts) with Her2-Positive Metastatic Breast Cancer (Mbc)(2014)37 cited
- → Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study(2018)36 cited
- → Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial(2022)17 cited